Russell F. DeVore

4.9k total citations · 2 hit papers
29 papers, 3.8k citations indexed

About

Russell F. DeVore is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Russell F. DeVore has authored 29 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 15 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Russell F. DeVore's work include Lung Cancer Research Studies (15 papers), Cancer therapeutics and mechanisms (14 papers) and Lung Cancer Treatments and Mutations (9 papers). Russell F. DeVore is often cited by papers focused on Lung Cancer Research Studies (15 papers), Cancer therapeutics and mechanisms (14 papers) and Lung Cancer Treatments and Mutations (9 papers). Russell F. DeVore collaborates with scholars based in United States, Taiwan and Canada. Russell F. DeVore's co-authors include David H. Johnson, Jacques Gaudreault, David M. Jablons, Eric Holmgren, John Nemunaitis, William Novotny, Roy S. Herbst, Louis Fehrenbacher, Corey J. Langer and Fairooz F. Kabbinavar and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and Cancer.

In The Last Decade

Russell F. DeVore

28 papers receiving 3.7k citations

Hit Papers

Randomized Phase II Trial Comparing Bevacizumab Plus Carb... 2000 2026 2008 2017 2004 2000 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
    2004 1.5k citations David H. Johnson, Louis Fehrenbacher et al. Journal of Clinical Oncology profile →
  2. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
    2000 1.1k citations Frank V. Fossella, Russell F. DeVore et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Russell F. DeVore United States 17 2.8k 2.4k 1.3k 460 374 29 3.8k
Vera Gorbounova Russia 13 2.2k 0.8× 1.8k 0.8× 617 0.5× 354 0.8× 407 1.1× 23 3.2k
Mark S. Huberman United States 30 3.0k 1.1× 3.3k 1.4× 1.2k 1.0× 778 1.7× 220 0.6× 80 4.5k
Aleksandra Szczęsna Poland 23 4.4k 1.6× 4.2k 1.7× 1.2k 0.9× 665 1.4× 463 1.2× 73 5.8k
Francesco Orlandi United States 17 4.9k 1.8× 3.2k 1.3× 806 0.6× 565 1.2× 887 2.4× 39 5.6k
Bilal Piperdi United States 35 3.9k 1.4× 2.8k 1.1× 821 0.6× 518 1.1× 529 1.4× 119 5.0k
G. Robinet France 23 2.1k 0.8× 2.3k 1.0× 522 0.4× 325 0.7× 172 0.5× 110 3.0k
Joo Hang Kim South Korea 27 1.9k 0.7× 1.9k 0.8× 789 0.6× 426 0.9× 209 0.6× 91 3.0k
Shinzoh Kudoh Japan 27 4.0k 1.4× 4.5k 1.9× 1.3k 1.0× 489 1.1× 278 0.7× 84 5.7k
Francisco Robert United States 28 1.8k 0.6× 1.4k 0.6× 1.1k 0.9× 312 0.7× 338 0.9× 107 3.2k
Lorinda Simms United States 18 3.5k 1.3× 3.6k 1.5× 997 0.8× 848 1.8× 165 0.4× 38 5.1k

Countries citing papers authored by Russell F. DeVore

Since Specialization
Citations

This map shows the geographic impact of Russell F. DeVore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Russell F. DeVore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Russell F. DeVore more than expected).

Fields of papers citing papers by Russell F. DeVore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Russell F. DeVore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Russell F. DeVore. The network helps show where Russell F. DeVore may publish in the future.

Co-authorship network of co-authors of Russell F. DeVore

This figure shows the co-authorship network connecting the top 25 collaborators of Russell F. DeVore. A scholar is included among the top collaborators of Russell F. DeVore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Russell F. DeVore. Russell F. DeVore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Horn, Leora, Zhiguo Zhao, Alan Sandler, et al.. (2011). A Phase II Study of Carboplatin and Irinotecan in Extensive Stage Small-Cell Lung Cancer. Clinical Lung Cancer. 12(3). 161–165. 5 indexed citations
2.
Johnson, David H., Louis Fehrenbacher, William Novotny, et al.. (2004). Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 22(11). 2184–2191. 1516 indexed citations breakdown →
3.
Masters, Gregory A., Lieven Declerck, Charles D. Blanke, et al.. (2003). Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597. Journal of Clinical Oncology. 21(8). 1550–1555. 97 indexed citations
4.
Roberts, John R., et al.. (2001). Induction chemotherapy increases perioperative complications in patients undergoing resection for non–small cell lung cancer. The Annals of Thoracic Surgery. 72(3). 885–888. 91 indexed citations
5.
Dowell, Jonathan E., et al.. (2001). A Phase II trial of 6-Hydroxymethylacylfulvene (MGI-114, Irofulven) in Patients with Advanced Non-Small Cell Cancer Previously Treated with Chemotherapy. Investigational New Drugs. 19(1). 85–88. 16 indexed citations
6.
Choy, Hak, Russell F. DeVore, Kenneth R. Hande, et al.. (2000). A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non–small-cell lung cancer (a Vanderbilt cancer center affiliate network study). International Journal of Radiation Oncology*Biology*Physics. 47(4). 931–937. 81 indexed citations
7.
Fossella, Frank V., Russell F. DeVore, Jeffrey Crawford, et al.. (2000). Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens. Journal of Clinical Oncology. 18(12). 2354–2362. 1124 indexed citations breakdown →
8.
Gandara, David R., Everett E. Vokes, Mark A. Green, et al.. (2000). Activity of Docetaxel in Platinum-Treated Non–Small-Cell Lung Cancer: Results of a Phase II Multicenter Trial. Journal of Clinical Oncology. 18(1). 131–131. 125 indexed citations
9.
Higa, Gerald M., Mohamadi Sarkar, & Russell F. DeVore. (1999). Pharmacodynamic Profile of Prolonged Etoposide Administration in Patients with Small Cell Lung Cancer and Non‐Hodgkin's Lymphoma. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 19(1). 101–107. 10 indexed citations
10.
Rothenberg, Mace L., John V. Cox, Russell F. DeVore, et al.. (1999). A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 85(4). 786–795. 162 indexed citations
11.
Belani, Chandra P., Philip Bonomi, Russell F. DeVore, et al.. (1999). Docetaxel and Cisplatin in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC): A Multicenter Phase II Trial. Clinical Lung Cancer. 1(2). 144–150. 13 indexed citations
12.
Higa, Gerald M., Russell F. DeVore, Miklos Auber, Joseph P. Lynch, & Kenneth S. Landreth. (1998). Biological and Clinical Correlates after Chemotherapy and Granulocyte Colony‐Stimulating Factor Administration. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 18(1). 1–8.
13.
DeVore, Russell F., Carl G. Hellerqvist, Barbara D. Wamil, et al.. (1997). Phase I study of the antineovascularization drug CM101.. PubMed. 3(3). 365–72. 35 indexed citations
14.
Chiappori, Alberto, Russell F. DeVore, & David H. Johnson. (1997). New Agents in the Management of Non-Small-Cell Lung Cancer. Cancer Control. 4(4). 317–325. 6 indexed citations
15.
Wamil, Barbara D., et al.. (1997). Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial. Journal of Cancer Research and Clinical Oncology. 123(3). 173–179. 21 indexed citations
16.
Johnson, David H., Russell F. DeVore, F. Anthony Greco, et al.. (1992). Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.. PubMed. 19(1 Suppl 2). 50–6. 5 indexed citations
17.
Johnson, David H., et al.. (1992). Carboplatin plus Oral Etoposide in the Management of Unresectable Non-Small Cell Lung Cancer. Oncology. 49(1). 57–62. 9 indexed citations
18.
Murphy, Patrick, John D. Hainsworth, F. Anthony Greco, et al.. (1992). A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. Cancer. 69(2). 370–375. 28 indexed citations
19.
DeVore, Russell F., Anita H. Corbett, & Neil Osheroff. (1992). Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.. PubMed. 52(8). 2156–61. 84 indexed citations
20.
DeVore, Russell F., et al.. (1989). Therapy-Related Acute Nonlymphocytic Leukemia with Monocytic Features and Rearrangement of Chromosome 11q. Annals of Internal Medicine. 110(9). 740–742. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vera Gorbounova Breakdown of academic impact, for papers by Mark S. Huberman Breakdown of academic impact, for papers by Aleksandra Szczęsna Breakdown of academic impact, for papers by Francesco Orlandi Breakdown of academic impact, for papers by Bilal Piperdi Breakdown of academic impact, for papers by G. Robinet Breakdown of academic impact, for papers by Joo Hang Kim Breakdown of academic impact, for papers by Shinzoh Kudoh Breakdown of academic impact, for papers by Francisco Robert Breakdown of academic impact, for papers by Lorinda Simms
Rankless by CCL
2026